Here we investigate the molecular mechanism(s) by which four CLD-causing mutations (ΔY526/7, I544N, I675/6ins and G702Tins) in the STAS domain lead to disease. In a heterologous mammalian expression system biochemical, immunohistochemical and ion transport experiments suggest that the four CLD mutations cause SLC26A3 transporter misfolding and/or mistrafficking. Expression studies with the isolated STAS domain suggest that the I675/6ins and G702Tins mutations disrupt the STAS domain directly, while limited proteolysis experiments suggest that the ΔY526/7 and I544N mutations affect a later step in the folding and/or trafficking pathway. The data suggest that these CLD-causing mutations cause disease by at least two distinct molecular mechanisms, both ultimately leading to loss of functional protein at the plasma membrane.
exchanger, cause CLD. SLC26A3 is a membrane protein predicted to contain 12 transmembrane spanning α-helices and a C-terminal STAS domain homologous to the bacterial anti-sigma factor antagonists. The STAS domain is required for SLC26A3 Cl -/HCO 3 -exchange function and for the activation of CFTR by SLC26A3.
Here we investigate the molecular mechanism(s) by which four CLD-causing mutations (ΔY526/7, I544N, I675/6ins and G702Tins) in the STAS domain lead to disease. In a heterologous mammalian expression system biochemical, immunohistochemical and ion transport experiments suggest that the four CLD mutations cause SLC26A3 transporter misfolding and/or mistrafficking. Expression studies with the isolated STAS domain suggest that the I675/6ins and G702Tins mutations disrupt the STAS domain directly, while limited proteolysis experiments suggest that the ΔY526/7 and I544N mutations affect a later step in the folding and/or trafficking pathway. The data suggest that these CLD-causing mutations cause disease by at least two distinct molecular mechanisms, both ultimately leading to loss of functional protein at the plasma membrane.
The solute carrier family 26 (SLC26A) is a recently described protein family containing ten human genes (1) (2) (3) . These genes encode membrane proteins which are predicted to contain between ten and fourteen transmembrane spanning α-helices and a C-terminal domain (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . The family members have varied tissue distributions, some being expressed in most organs and others with more restricted tissue expression patterns (1, 4, 6, 12, (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) .
The SLC26A proteins function as anion exchangers or Cl -channels in the luminal membrane of epithelial cells, transport solutes including oxalate, SO 4 -, I -, Cl -, HCO 3 -, NO 3 -, SCN -, OH -, and thus, are important in a number of physiological processes (9, 19, 20, (23) (24) (25) (26) (27) (28) .
SLC26A3 was first identified as a gene that was down regulated in human colon adenocarcinomas and subsequently named DRA (29) . Thus far, SLC26A3 has not been conclusively demonstrated to be a tumor suppressor gene (30, 31) , but it has been unequivocally demonstrated to be a Cl -/HCO 3 -exchanger with a 2:1 transport stoichiometry (27, (30) (31) (32) (33) . The transport function of SLC26A3 is thought to play an important role in Cl -absorption and HCO 3 -secretion in the colon and perhaps the pancreas (4, 9, (30) (31) (32) (33) .
The highly conserved C-terminal domain of the SLC26A proteins has been demonstrated to be important for proper ion transport activity (29, (32) (33) (34) (35) (36) . This C-terminal domain is homologous to the SpoIIAA family of antisigma-factor antagonists (37), which controls bacterial sporulation through a protein-protein interaction with the antisigmafactors (38) (39) (40) , an interaction that is regulated by phosphorylation (41) (42) (43) (44) .
Since the SLC26A proteins were originally predicted to be sulfate transporters, their C-terminally conserved domain was named STAS for sulfate transporters and antisigma-factor antagonists (37). Similar to the antisigmafactor antagonists, phosphorylation regulates the interaction between the SLC26A3 STAS domain and the R-domain of CFTR (33) . The STAS and R-domain interaction coordinately activates CFTR's Cl -channel activity and SLC26A3's Cl -/HCO 3 -exchange activity (33) as required for epithelial function.
Mutations in four of the SLC26A transporters have been liked to human diseases (45) (46) (47) (48) (49) (50) (51) . Mutations in SLC26A2 (also known as DTDST) have been linked to various chondrodysplasias which cause skeletal defects including clubbed feet, cleft palate and short limbed dwarfism (47, 48, 51) . Mutations in the SLC26A4 gene (also known as Pendrin or PDS) have been linked to Pendred Syndrome which is the most common form of syndromic deafness (45, 46, 50) , while mutations in the SLC26A5 gene (also known as Prestin) have been linked to non-syndromic deafness (49) .
Mutations found in the SLC26A3 gene have been linked to congenital chloride-losing diarrhea (CLD) (4), a disease in which patients suffer from watery diarrhea containing elevated Cl -concentrations that can prove fatal if left untreated (52) . Clinical management of the disease includes increased dietary uptake of water, KCl and NaCl (52, 53) . A recent report also suggests butyrate is effective in controlling the patient's diarrhea (54) .
Currently, over 30 mutations in SLC26A3 have been linked to CLD (8, 14, 52) . Four of these mutations are missense, deletion or insertion mutations that reside in the STAS domain of SLC26A3 (ΔY526/7, I544N, I675/6ins and G702T + GFEVKIQNF insertion (G702Tins)).
The I544N and I675/6ins mutations have been demonstrated to cause a loss of measurable transport activity of the human and mouse SLC26A3 protein respectively (32) (33) (34) , however the mechanism by which these mutations undermine function is unknown. The effects of the ΔY526/7 and G702Tins mutations on SLC26A3 protein function and folding are also unknown. To elucidate the molecular mechanism(s) by which these CLD-causing mutations give rise to disease, we functionally, biochemically and cell biologically characterized the wild type and mutant transporters. In addition, we monitored the effect of the CLD-causing mutations on the isolated STAS domain. These data suggest distinct mechanisms by which the CLD-causing mutations lead to disease.
Experimental Procedures
Plasmid construction: Mammalian expression constructs for full length human SLC26A3 protein (gi:4557534) were constructed using standard molecular biology techniques and cloned into the BglII and NotI restriction sites of the pCMV-Myc vector (Clontech) resulting in a protein construct with a N-terminal Myc tag. Site directed mutagenesis was performed using PfuTurbo DNA polymerase (Stratagene) to generate the in-frame deletion ΔY526/7, I544N, I675/6ins and G702Tins mutant constructs. Constructs for mammalian cell expression of human SLC26A3 STAS domain constructs were generated with domain boundaries encompassing residues 509-741, and were cloned into the BglII and NotI sites of the pCMV-Myc vector, while nine different human STAS domain constructs for bacterial expression were cloned into the BamHI site of the Smt3-pET28 vector using the combination of three N-terminal domain boundaries (amino acids 503, 510 and 525) and three C-terminal domain boundaries (720, 741 and 764) (55) . All of these constructs were N-terminal fusions with the His 6 -Smt3 protein and were verified by DNA sequencing.
Cl
-/HCO 3 -Exchange Activity: HeLa cells grown on glass cover slips were transfected with the appropriate SLC26A3 plasmid along with a GFP expression plasmid. 3 μl of Fugene 6 (Roche) was used per transfection, and the cells were used for Cl -/HCO 3 exchange measurements 48 hrs post transfection. GFP positive cells were selected on a fluorescence microscope (Nikon) and incubated with 10 μM 2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl ester (BCECF-AM) (Molecular Probes) and 0.2% Pluronic F-127 (Molecular Probes) for 10 min in HEPES Buffer (10 mM HEPES pH 7.4, 140 mM sodium chloride, 5 mM potassium chloride, 1 mM magnesium chloride, 1 mM calcium chloride, 10 mM Glucose, osmolarity (Osm) 310 mOsm). Cells were perfused with HEPES buffer until a steady baseline was achieved, then cells were perfused with HCO 3 -buffer for 3 min (2.5 mM HEPES pH 7.4, 120 mM sodium chloride, 5 mM potassium chloride, 1 mM magnesium chloride, 1 mM calcium chloride, 10 mM Glucose, 260 mOsm, then 25 mM of sodium bicarbonate was added). Subsequently the cells were perfused with Cl -free buffer for 3 min (2.5 mM HEPES pH 7.4, 120 mM sodium gluconate, 5 mM potassium gluconate , 1 mM magnesium sulfate, 1 mM cyclamic acid, 10 mM Glucose, 260 mOsm then 25 mM sodium bicarbonate was added), followed by a 3 min perfusion with HCO 3 -buffer. Finally, the cells were perfused with HEPES buffer for 3 min. 5% carbon dioxide gas was bubbled through buffers containing bicarbonate throughout the experiment. The change in the fluorescence excitation ratio of BCECF-AM was monitored at 490nm/440nm with the emission at 510 nm. pH i was calibrated using three standard buffers containing 10 mM HEPES, 140 mM potassium chloride, 1 mM magnesium chloride, 1 mM calcium chloride, 10 mM glucose and 5 μM nigercin at pH 6.65, 7.4 and 8.15.
Immunofluorescence: HeLa and COS-7 cells were grown on glass cover slips (Fisher) in 35mm dishes using DMEM (Gibco) containing 10% calf serum (Gemini) and supplemented with penicillin and streptomycin at 37°C or 30°C in a humidified incubator with 5% carbon dioxide. HeLa cells were transfected with 1μg of wild type or mutant SLC26A3 pDNA using Fugene 6 following the manufacture's protocol.
48 hr post transfection cells were washed twice with PBS and fixed in 3.7% formaldehyde for 20 min and subsequently washed twice for 5 min in PBS. Cells were permeablized with 0.1% Triton X-100 in PBS for 10 min at room temperature followed by two washes with PBS. The permeablized cells were incubated for 20 min in blocking solution (1.3% fish skin gelatin and 1% BSA in PBS) followed by a 1 hr incubation with a 1:100 dilution of rabbit anti-Grp78 (Bip) (Stressgen), 1:500 anti-cMyc (Santa Cruz Biotechnology) and a 1:500 Phalloidin conjugated to tetramethylrhodamine isothiocyanate (TRITC) (Sigma) in blocking solution. The cells were subsequently washed twice with PBS for 5 min and then incubated with a 1:100 dilution of the anti-rabbit antibody conjugated to cyanine-5. 18 (cy5) (Jackson Immuno Research) and a 1:500 dilution of anti-mouse antibody conjugated to fluorescein isothiocyanate (FITC) (Jackson Immuno Research) in blocking solution. Cells were washed and mounted using gel mount (Biomedia). Staining cells with the STAS domain antibody required a change of secondary antibody species, but the same protocol was used as described above. A 1:500 dilution of the STAS domain antibody was used along with a 1:100 dilution of mouse anti-Grp78 (BiP) (Stressgen). The secondary antibodies were a 1:500 dilution of anti-rabbit antibody conjugated to (FITC) (Jackson Immuno Research) and a 1:100 dilution of the anti-mouse antibody conjugated to (cy5) (Jackson Immuno Research). All stained cells were visualized and images collected using a Ziess confocal microscope and Zeiss LSM 510 software version 2.8.
Glycosylation Assay: COS-7 cells grown in DMEM (Gibco) containing 10% calf serum (Gemini) supplemented with penicillin and streptomycin at 37°C or 30°C in a humidified incubator with 5% CO 2 . 35 mm dishes of COS-7 cells were transfected with 1 μg of wild type or mutant SLC26A3 pDNA using Fugene 6 (Roche) following the manufacture's guidelines. 48 hr post transfection the cells were washed twice with 0.5 ml TBS and then lysed in 0.5 ml of RIPA buffer (20 600 measurements were taken and used to ensure that the same number of cells were pelleted at 4°C at 3000 x g. The cell pellets were then resuspended in 20 ml of lysing buffer (20 mM Tris pH 7.9, 200 mM sodium chloride, 1 mM 2-mercapto ethanol) and lysed via sonication with a Branford 450 Sonicator on power level 4, duty cycle 60%, three times for 30 sec. The resulting lysates were cleared via a 40,000 x g centrifugation step at 4°C for 30 min. Equal volumes of cell lysates were separated by SDS-PAGE and stained with coomassie blue or transferred for western blot analysis.
HEK 293 cells were transiently transfected with wild type and mutant pCMVMyc SLC26A3 STAS domains, and incubated at 37ºC for 48 hr and subsequently scraped off the plate in 0.5 ml of lysing buffer. The cells were lysed by sonication and centrifuged at 60,000 x g for 30 min at 4ºC. Equivalent amounts of protein were loaded on the gel as determined by a Bradford assay.
Western Blotting:
SDS-PAGE gels for western blots were transferred to PVDF membrane (Millipore) using the wet transfer method in Tris/Glycine transfer buffer containing 10% methanol. Membranes were blocked using 5% milk (BioRad) in TBS containing 0.05% Tween 20 (Sigma), and primary and secondary antibody incubations were performed in blocking buffer. Primary antibody dilutions were as follows; a 1:1000 dilution of the anti-His 6 (Novagen), a 1:3000 dilution of the anti-c-Myc (Santa Cruz Biotechnology) and a 1:5000 dilution of the anti-STAS antibody.
Secondary antibody dilutions were as follows; and shifted to 15°C for overnight expression. The following day the cells were pelleted at 3000 x g and resuspended in 70 ml of lysing buffer. The cells were lysed via sonication and the resulting lysates cleared by centrifugation at 40,000 x g. Standard Ni chromatography was performed on the resulting supernatants using 10 ml bed volume of resin (Novagen). The equilibration/binding buffer (buffer A) contained 20 mM Tris pH 7.9, 200 mM sodium chloride, 1 mM 2-mercapto ethanol, the column was washed using buffer A containing 40 mM imidazol and the protein was eluted from the column using buffer A containing 400 mM imidazole. Fractions containing the Smt3-STAS fusion protein were pooled together and digested overnight with a 1:1000 dilution of the Ulp1 protease at 4°C (55) .
Ammonium sulfate (750 mM) was added to the cleaved protein solution, then run through a 0.22 μm filter (Nalgene), and then subjected to butyl hydrophobic interaction chromatography (Amersham Biosciences). The equilibration/binding buffer contained 20 mM sodium phosphate pH 5.9, 750 mM ammonium sulfate, 1 mM DTT and the elution buffer contained 20 mM sodium phosphate pH 6.2, 1 mM DTT. Fractions containing the STAS protein were pooled together and 350 mM sodium chloride was added to the solution. The protein was concentrated to 2 ml using an Amicon Ultra concentrator (5,000 MWCO) at 4°C in a swinging bucket rotor, run through a 0.22 μm filter (Nalgene), and run over a HiPrep 16/60 Sephacryl S-200 column (Amersham Biosciences) in 20 mM sodium phosphate pH 6.2, 350 mM sodium chloride, 1 mM DTT. Monodisperse STASdomain containing fractions were pooled and concentrated as needed. The molecular weight of the STAS domain was estimated by the elution profile of protein standards and is consistent with a monomer.
Circular Dichroism:
Circular dichroism spectra were measured using an AVIV 62DS spectrophotometer with a 0.1 cm quartz cuvette. The STAS CD spectra and thermal denaturation curves were collected at 10 μM in 20 mM sodium phosphate pH 6.2, 350 mM sodium chloride, 1_mM DTT. 15 N wild type and ΔY526/7 SLC26A3 STAS domain were expressed in M9 minimal media with 15 N ammonium chloride as the nitrogen source, supplemented with 5% uniformly 15 N-labeled BioExpress cell growth media (Cambridge Isotope Laboratories). The proteins were purified as described above with the only change being that the protein was eluted off of the gel filtration column in 50 mM potassium phosphate pH 6.8, 400 mM potassium chloride, 100 mM arginine, 2% glucose, 2 mM DTT. TROSY-HSQC spectra (56) of 90 μM purified wild-type and ΔY526/7 STAS domains were collected using a 600 MHz Varian Inova spectrometer with a pulsed-field gradient, triple resonance cold probe at 30°C for 12 hrs each. Spectra were processed with NMRPipe (57) and displayed with NMRView (58).
NMR Spectroscopy: Uniformly isotopically enriched

STAS Domain Antibody
Production: Recombinantly expressed and purified SLC26A3 STAS domain protein (described above) was used as the antigen for rabbit polyclonal antibody production. Briefly, 5 mg of purified protein was shipped to Proteintech Group Inc. for injection of two rabbits following their standard 102 day protocol. Two production bleeds and a final bleed from each animal were tested for their reactivity to the STAS domain protein, and all six antiserum samples were found to detect the STAS domain protein in a similar fashion. The STAS domain antibody has been shown to crossreact with mouse SLC26A3, SLC26A6, SLC26A7 and SLC26A9 proteins as well as with human SLC26A6 and SLC26A11 proteins.
The ability of the antisera to recognize other SLC26A transporters has not been evaluated.
Tryptic Digests: Transiently transfected HEK 293 cells were allowed to express the wild type and mutant SLC26A3 proteins for 48 hr at which time they were washed twice with TBS and scraped off the plate in 500 μl of 10 mM HEPES pH 7.4 200 mM sucrose. The cells were sonicated twice for 20 seconds on the lowest power setting and placed on ice. The resulting lysates were incubated in the presence of increasing concentrations of Trypsin (0.3, 1, 3, 10, 30, 100 and 300 μg/ml) at room temperature for 12 min.
The digestions were stopped with SDS sample buffer and the digested protein was separated by SDS-PAGE and then transferred to PVDF membrane. The western blot was performed as described above using the anti-STAS antibody, and densitometry was performed on representative western blots using the ImageJ program.
Results
A number of structural models have been suggested for the SLC26A transporters which differ in the number of transmembrane segments, their topology, the location of the N and C-termini and the boundaries of the STAS domain. While the vast majority of SLC26A topology predictions suggest these proteins contain an even number of transmembrane spans with their N and C-termini located in the cytosol (1, 4, 5, (7) (8) (9) (10) (11) (12) (13) 18, (59) (60) (61) , some topology models have suggested an odd number of transmembrane spans (22, 62) , or that the N and C-termini are extracellularly located (63) . To identify the most appropriate topology model for SLC26A3, the location of the Ntermini and the conserved C-terminal STAS domain were determined ( Figure 1A) . Immunofluorescence experiments were performed with HeLa cells transfected with empty vector, the SLC26A3 STAS domain or the complete SLC26A3 transporter. Cells were then permeabilized by incubation with Triton X-100 or left untreated to determine the topology. N-terminal Myc-tag or C-terminal STAS domain staining was only observed in permeabilized cells ( Figure 1B and C), indicating that both termini are cytosolic. However, these experiments cannot rule out the possibility that the detergent treatment exposed extracellular epitopes that are inaccessible to the antibodies in the absence of detergent.
To further characterize the SLC26A3 protein we decided to identify the domain boundaries of the STAS domain. As an initial step in determining the domain boundaries, a STAS domain multiple sequence alignment was generated (Figure 2 ). From the alignment it is immediately apparent that the SLC26A STAS domains contain a large insertion of sequence compared to their structural homologs, the SpoIIAA proteins.
The sequence in the SLC26A STAS domains not found in the SpoIIAA proteins is designated as the intervening sequence (IVS). The first twenty amino acids of the IVS show limited conservation among the SLC26A STAS domains, and a secondary structure prediction of these residues suggests that a portion of this sequence is α-helical in nature.
The remaining residues in the IVS show no sequence conservation in the various SLC26A transporters, and secondary structure predictions of this region suggest they are largely unstructured.
The poor sequence conservation between the SLC26A proteins and the SpoIIAA proteins makes it difficult to predict the N and C-terminal boundaries of the SLC26A3 STAS domain. To identify the N and C-terminal boundaries of the STAS domain, a matrix of three N-terminal boundaries (amino acids 503, 510 and 525) and three C-terminal boundaries (amino acids 720, 741 and 764) was used to produce nine possible SLC26A3 STAS constructs. All were expressed in E. coli, and the three constructs ending in amino acid 720 were insoluble after cell lysis and a 40,000 x g centrifugation step (data not shown).
The remaining six constructs had greater than 50% of the total expressed protein in the supernatant fraction. These six were evaluated for secondary structure, thermal stability and their ability to bind to the R-domain of CFTR (supplemental Figure 1 ). Based on this data (see below), the STAS domain construct with domain boundaries of 510-741 was selected for further study.
With the topology of SLC26A3 elucidated and the STAS domain boundaries identified, we set out to understand how mutations in the cytosolic STAS domain of SLC26A3 lead to disease. We began by measuring chloride-bicarbonate exchange (Cl -/HCO 3 -) activity of the wild type and mutant transporters in HeLa cells using the pH sensitive fluorescent dye BCECF-AM as previously described (64 Figure 1A ). Using this assay Cl -/HCO 3 -exchange activity was observed for the wild type and ΔY526/7 SLC26A3 proteins ( Figure 3A) , with the exchange rate of the ΔY526/7 mutant reduced by 46% relative to wild type ( Figure 3B ). No significant Cl -/HCO 3 -exchange activity was observed for the I544N, I675/6ins and G702Tins mutant transporters ( Figure 3A and 3B) .
Two Figure 4A ). The western blot revealed two bands for the untreated wild type transporter with the higher molecular weight species being the predominant band. Upon treatment of the wild type lysates with EndoH the migration of the lower molecular weight species was accelerated, indicating it was core glycosylated and integrated into the ER membrane. Upon PNGaseF treatment of the wild type lysates, migration of both bands shifted to this lowest molecular weight species, consistent with the higher molecular weight species being a complexly glycosylated SLC26A3 protein that has trafficked to the Golgi apparatus or beyond. The bulk of the ΔY526/7 SLC26A3 protein was core glycosylated with only a small amount of complexly glycosylated protein. The I544N, I675/6ins and G702Tins mutants were all core glycosylated but contained no observable complexly glycosylated protein, suggesting that these CLD-causing mutations give rise to the disease by preventing proper trafficking to the plasma membrane. In addition, it is worth noting that at steady state, the expression levels of the I675/6ins and G702Tins mutant SLC26A3 proteins are consistently reduced compared to the wild type, ΔY526/7 and I544N mutant transporters consistent with their recognition by proteolytic systems of the cell.
The cellular location of the wild type and mutant SLC26A3 transporters was also determined by performing immunofluorescence experiments. In HeLa cells expressing SLC26A3 the wild type transporter is found in the plasma membrane and in the ER ( Figure 4B ). Cells transfected with the ΔY526/7 transporter showed two distinct populations of cells. One population of cells showed the ΔY526/7 transporter at the plasma membrane ( Figure 4B, row 3) , and the other showed ER retention ( Figure 4B row 2) . The I544N, I675/6ins and G702Tins mutant transporters all show ER localization ( Figure  4B rows 4, 5, and 6). Identical results were observed in the COS-7 cells (data not shown). To exclude any possible epitope effects that may contribute to the observed subcellular localization of the wild type and mutant transporters, we also performed immunofluorescence experiments using the anti-STAS domain antibody. The staining pattern for the SLC26A3 transporters using the anti-STAS domain antibody was indistinguishable compared to the anti-c-Myc antibody in both HeLa and COS-7 cells (data not shown).
In an attempt to rescue the CLDcausing mutations that affect proper trafficking out of the ER, we reduced the expression temperature from 37ºC to 30ºC and monitored the amount of the complexly glycosylated protein produced. Transiently transfected COS-7 cells were incubated at 37 ºC for 24 hr, and then shifted to 30ºC for an additional 24 hr. The manipulation led to a substantial increase in the amount of the complexly glycosylated ΔY526/7 mutant transporter, while a decrease was observed in the amount of complexly glycosylated wild type protein ( Figure 5A compared to Figure  4A ). In contrast to the ΔY526/7 transporter, the I544N, I675/6ins or G702Tins transporters were not complexly glycosylated upon low temperature treatment ( Figure  5A ). Immunofluorescence experiments were also performed to assess the subcellular localization of the wild type and mutant transporters when expressed at 30ºC ( Figure  5B) . Consistent with the biochemical data, the vast majority of ΔY526/7 mutant transporter was found to be localized to the plasma membrane at 30ºC, highlighting the temperature sensitivity of this mutant. The increase in plasma membrane expression at low temperature was not observed for the I544N, I675/6ins and G702Tins mutants, which all show ER localization and vacuolation.
To further substantiate this finding and determine if the plasma membrane targeted ΔY526/7 is active, Cl -/HCO 3 -exchange activity of the wild type and ΔY526/7 mutant transporters was measured ( Figure 5C ). By contrast to the functional measurements made at 37ºC, the Cl -/HCO 3 -exchange rate of the ΔY526/7 mutant transporter at 30ºC approached that of wild type ( Figure 5D ). The reduced ability of the ΔY526/7 mutant SLC26A3 transporter to traffic to the plasma membrane, and the lack of plasma membrane trafficking of the I544N, I675/6ins and G702Tins mutants, suggested that these mutations may be causing the transporters to misfold. To investigate the possibility that these mutations specifically disrupt folding of the STAS domain, the wild type and mutant STAS domains were recombinantly expressed in order to study their biochemical and biophysical properties.
Using the SLC26A3 STAS domain boundaries of 510-741, we created Smt3-STAS fusions of the wild type and mutant proteins and assessed their ability to fold by monitoring solubility in E.coli. The wild type, ΔY526/7 and I544N STAS domains were found to be solubly expressed in E.coli while the I675/6ins and G702Tins SLC26A3 STAS domains were found to be produced in an insoluble form ( Figure 6A) . A similar pattern of solubility/folding was observed when the STAS domains were produced in HEK 293 ( Figure 6B ) and COS-7 cells (data not shown), suggesting that the effects of the mutations on STAS domain folding is independent of the cell line used.
The solubly expressed wild type, ΔY526/7 and I544N STAS domains were purified ( Figure 7A ) and biophysical analysis using NMR and CD spectroscopies were performed ( Figure 7B, C and D) . The TROSY-HSQC spectrum of the wild type SLC26A3 STAS domain shows nitrogenproton cross peaks with chemical shift dispersions typical of a well folded protein, with peaks in the center of the spectrum likely from flexible loops, termini, or the IVS ( Figure 7B, black peaks) . A TROSY-HSQC spectrum of the ΔY526/7 STAS domain ( Figure 7B , red peaks) overlays well with the wild-type spectrum with only minor differences, consistent with absence of peaks and local chemical shift changes near the site of the mutation. In addition to the TROSY-HSQC spectra, CD spectra were collected for the wild type, ΔY526/7 and I544N STAS domains. The CD spectra for the wild type and two mutant STAS domains are indistinguishable from one another, and indicate that the STAS domain is a mixed α/β protein, consistent with the predicted structure of the STAS domain ( Figure 7C ). Thermal stability measurements were made of the wild type, ΔY526/7 and I544N STAS domains by monitoring the loss of molar elipticity at 222_nm as the temperature was increased from 20°C to 80°C. No significant differences were observed between the wild type, ΔY526/7 and I544N STAS domains denaturation curves with all three proteins having melting temperature (T m ) values of 53ºC ( Figure 7D ).
Although the ΔY526/7 and I544N mutations cause a partial or complete loss of plasma membrane trafficking of the transporter, no measurable differences in the domain itself were observed. By inference, the ΔY526/7 and I544N mutations may affect the ability of the STAS domain to interact with other regions of the transporter. To test this, the conformation of SLC26A3 was assessed by limited proteolysis of the wild type and mutant transporters with trypsin. Increasing concentrations of trypsin were incubated with the lysates at room temperature for 12 min and the reactions were stopped by the addition of sample buffer. Tryptic fragments were detected via western blot analysis using the STAS domain antibody, which detect the full length protein (FL) and three predominant proteolytic fragments labeled 1-3 ( Figure 8A ). Consistent with their STAS domains being misfolded and more readily degraded, the I675/6ins and G702Tins transporters are more susceptible to proteolysis than are the wild type, ΔY526/7 and I544N transporters.
More subtle conformational differences between the wild type and the ΔY526/7 and I544N transporters are also observed. Quantification of the degradation patterns of the full length transporters ( Figure 8B ) reveal measurable differences between the wild type and the I544N transporters at the typsin concentrations encompassing 3-100 μg/ml (P values lower than 0.05), where no significant differences are observed between the wild type and ΔY526/7 transporters. The most profound difference between the wild type, ΔY526/7 and I544N transporters is in the production of proteolytic fragment 1 ( Figure 8D ). This data taken together suggests that the ΔY526/7 and I544N mutations may cause conformational changes in the transporter due to altered domain-domain interactions.
Discussion
Multiple topology models have been presented for the SLC26A family, with the most frequently published model having the N and C-termini located in the cytosol (1, 4, 5, (7) (8) (9) (10) (11) (12) (13) 18, (59) (60) (61) . The experimental topology data presented here is the first to be reported for SLC26A3, and supports a model with intracellularly located N and C-termini. Consistent with our results, some previous studies on SLC26A5 and SLC26A6 have indicated that the N-and C-termini of these proteins are located in the cytosol (7, 10, 13, 61) . The location of the N-terminus is important as previous reports have reported it to be proteolytically cleaved in vivo (65, 66) , raising the possibility that proteolytic cleavage may regulate transporter function. However, in the current study the same banding pattern was observed in our western blots regardless of whether an N or C-terminal antibody was used (anti-c-Myc or anti-STAS domain, data not shown), suggesting that under our experimental conditions SLC26A3 is not undergoing any significant proteolysis. In addition, localizing the SLC26A3 STAS domain to the cytosol is consistent with the previously described model for CFTR activation by SLC26A3 (33) .
Indeed, establishing that the STAS domain of SLC26A3 is in the same subcellular compartment as the R-domain of CFTR is central to this model for HCO 3 -secretion. The boundaries of the cytosolic STAS domain have not yet been clearly identified; however, it must follow the final transmembrane segment of SLC26A3 which has been predicted to end between amino acids 494-497 (8,59). Thus, the SLC26A3 STAS domain is likely to begin somewhere after amino acid 500. The absence of a SLC26A STAS domain structure and the lack of strong sequence identity between the SLC26A STAS domains and SpoIIAA have made identifying the precise beginning of the domain difficult. In our expression studies the three N-terminal boundaries tested all resulted in soluble protein indicating that the N-terminus of the STAS domain may be at or C-terminal to amino acid 525. However, in our R-domain binding assay the N-terminal boundary of amino acid 510 resulted in more consistent binding which we interpret to indicate that the extra 15 amino acids on the N-terminus may aid in the binding interaction with the Rdomain, suggesting that the functional Nterminus is somewhere between amino acids 510 and 525. Constructs with a C-terminal boundary of amino acid 720 produced an insoluble STAS domain, while constructs ending in amino acid 741 were soluble. We interpret this data to indicate that the Cterminus of the STAS domain must be beyond amino acid 720, but likely not past amino acid 741. In addition to SLC26A3, the boundaries of a STAS domain homolog from Aquifex aeolicus VF5 (gi:15606490) were screened with similar results to those for SLC26A3. The optimal domain boundaries for soluble protein expression were amino acids 450-588 (analogous to amino acids 525-739 of SLC26A3) with an N-terminal boundary of amino acid 459 (analogous to amino acid 534 in SLC26A3) or a C-terminal boundary of 575 (analogous to amino acid 728 of SLC26A3) rendering the expressed protein insoluble (data not shown). In addition, a previous report used amino acid 497 as the N-terminal boundary for the SLC26A6 STAS domain, which is analogous to SLC26A3 amino acid 513 in SLC26A3 (67) . However, in this study the C-terminal boundary of SLC26A6 was defined to be amino acid 633, which from our multiple sequence alignment is predicted to be near the end of the IVS, suggesting that this construct is truncated at the C-terminus (67) . The present study provides a systematic analysis of STAS domain boundaries, and should aid in understanding the structural and functional properties of this domain.
The functional, glycosylation and immunofluorescence data presented suggests that the I544N, I675/6ins and G702Tins mutations result in CLD due to ER retention and the loss of functional protein at the plasma membrane. This is a common disease causing mechanism in the SLC26A protein family as a number of mutations in SLC26A2 and SLC26A4 have shown ER retention when monitored by immunofluorescence (11, 32, 48, 68) . It is interesting to note that the equivalent I675/6ins mutation in mouse SLC26A3 results in an inactive transporter that is properly trafficked to the plasma membrane (32) , suggesting that this mutation differentially effects the human and mouse transporters. The disease causing mechanism of the ΔY526/7 transporter is less clear since it retains some Cl -/HCO 3 -exchange activity, and hence some functional protein at the plasma membrane.
By lowering the expression temperature the amount of functional, plasma membrane localized and complexly glycosylated ΔY526/7 mutant transporter approached wild type levels.
This data suggests that the ΔY526/7 mutation is extremely sensitive to its cellular environment and is possibly a less severe mutation than the I544N, I675/6ins or G702Tins mutations. It should be noted that the ΔY526/7 mutant was identified in a patient who had the severe I675/6ins mutation on the other SLC26A3 allele (69).
While the major mechanism of disease seems to be ER retention, the CLD mutations have differential effects on the STAS domain itself. The I675/6ins and G702Tins mutations seem to prevent the STAS domain from folding as evident by the lack of soluble expression. We interpret the lack of solubly expressed protein to indicate protein misfolding. In contrast to the I675/6ins and G702Tins mutations, the ΔY526/7 and I544N mutations are solubly produced and do not cause dramatic changes in the measured biochemical or biophysical properties of the STAS domain. Nevertheless, the quality control machinery of the cell clearly recognizes the ΔY526/7 and I544N mutant transporters as different from the wild type transporter as evident by the mistrafficking of these proteins. It is possible that the ΔY526/7 and I544N mutations disrupt an interaction between the STAS domain and other regions of the SLC26A3 transporter that results in the recognition of this conformation as non-native by the cell.
The trypsin proteolysis experiments revealed different conformations for the mutant SLC26A3 transporters compared to the wild type, consistent with the hypothesis that the ΔY526/7 and I544N mutations disrupt domain-domain interactions.
A recent study on a SLC26A homolog from Arabidopsis thaliana also supports the hypothesis that the STAS domain may be involved in a domain-domain interaction. Shibagaki and Grossman performed random mutagenesis on the Sultr1.2 STAS domain from Arabidopsis thaliana, and identified a number of residues which are critical for proper sulfate transport and trafficking (36) . Three of the residues identified by Shibagaki and colleagues (Y523, A540 and Y542) are at positions similar to two of the CLD causing mutations (ΔY526/7 and I544N) in SLC26A3. The Y523H, A540S and Y542C Sultr1.2 mutants were all expressed and found to be in the plasma membrane, with the Y523H and Y542C mutations resulting in inactive transporters and the A540S mutant reducing transport activity. Shibagaki and Grossman mapped their mutants onto the SpoIIAA structure and found that many of their mutants, including Y523H, A540S and Y542C, cluster to the SpoIIAA-SpoIIAB binding interface. As a result, Shibagaki and Grossman speculated that molecular interactions on this surface may be important for proper Sultr1.2 transport activity (36) . Since SLC26A3 and Sultr1.2 are homologous, it is logical to think that the ΔY526/7 and I544N mutations may also disrupt an important domain-domain interaction however; in contrast to the Sultr1.2 mutants the CLD causing mutations in SLC26A3 inhibit proper folding.
Taken together, our data suggests a model by which the CLD-causing mutations in the STAS domain of SLC26A3 result in disease by causing a loss in wild type levels of functional protein at the plasma membrane ( Figure 9 ). The loss of functional transporters at the membrane is caused by at least two distinct mechanisms, both of which result in transporter mistrafficking and ER retention. The I675/6ins and G702Tins mutations cause the STAS domain to misfold, which prevents the mutant transporters from reaching the native state. In contrast, the ΔY526/7 and I544N mutations do not cause the STAS domain to misfold, but rather likely disrupt important intramolecular interactions critical to forming a well folded and functional transporter. However, we cannot rule out the possibility that additional intermolecular interactions critical for proper folding are also being disrupted by these two mutations. Hoglund, P., Auranen, M., Socha, J., Popinska, K., Nazer, H., Rajaram, U., Al Sanie, A., AlGhanim, M., Holmberg, C., de la Chapelle, A., and Kere, J. Scale bar is 50_μM. FIGURE 2: SLC26A3 STAS Alignment. The C-terminal STAS domains of ten SLC26A transporters from Homo sapiens were aligned with twelve Sultr family of sulfate transporters from Arabidopsis thaliana, four SpoIIAA proteins from Bacillus sphaericus, Bacillus subtilis, Geobacillus stearothermophilus and Thermotoga maritima and two predicted sulfate transporters from Desulfovibrio vulgaris Hildenborough and Aquifex aeolicus VF5. The alignment was generated using T-coffee and then shaded using the Boxshade program. The block arrows and tubes found below the alignment represent the α-helices and β-strands found in the three dimensional structures of the SpoIIAA proteins (44) . The line above the alignment denotes the intervening sequence (IVS) which is defined as the large sequence insertion in the STAS domains not present in the SpoIIAA homologues. The small filled arrows above the alignment indicate the various N and C-terminal boundaries used to screen for the optimal STAS domain boundaries. The asterisk indicates the position of known CLD-causing mutations found in the SLC26A3 STAS domain and the ρ symbol denotes the location of the conserved Ser residue in the SpoIIAA proteins which is phosphorylated (70). Residues shaded in red represent the carbonic anhydrase II binding site as described by Alvarez et al. (67) , while residues shaded in yellow indicate the residues which form the binding interface with SpoIIAB (71). The data presented are averaged data from at least three experiments from at least two independent protein preparations. Quantification of the loss of the wild type, ΔY526/7 and I544N SLC26A3 full length (FL) protein species at various trypsin concentrations. Each experiment was quantified and normalized independently of one another, and the mean and standard deviation were calculated from all experiments quantified (wild type n=5, ΔY527/6 n=5, I544N n=7). (C) Quantification of tryptic fragment 3 from the wild type, ΔY526/7 and I544N SLC26A3 trypsin digest experiments. The relative amounts of tryptic fragment 3 have been normalized to the most prevalent band within each individual experiment, and means and standard deviations were calculated from all experiments quantified (wild type n=5, ΔY527/6 n=5, I544N n=7). (D) Quantification of tryptic fragment 1 from the wild type, ΔY526/7 and I544N SLC26A3 trypsin digest experiments. The amount of tryptic fragment 1 in the 300 μg/ml trypsin lane was quantified via densitometry and then normalized to the average amount of wild type tryptic fragment. The mean and standard deviations are calculated from all experiments quantified (wild type n=5, ΔY527/6 n=6, I544N n=7). The wild type transporter and a portion of the ΔY526/7 transporters can adopt the appropriate structure which is recognized by the quality control machinery of the ER as native, and is then allowed to proceed through the secretory pathway where it is complexly glycosylated and eventually reaches the plasma membrane (PM). A portion of the ΔY526/7 transporters are retained in the ER and not trafficked to the plasma membrane. This misprocessing is more profound for the I544N, I675/6ins and G702Tins mutant transporters. The large and small font type for the ΔY526/7 labels represents the larger and smaller population of cells which have native like or non-native like transporter. This conceptual model has no information regarding the order by which the STAS and transmembrane domains fold and are assembled in the ER, rather it highlights the different mechanisms by which the STAS domain mutations bring about protein misfolding and the absence of active protein at the plasma membrane. 
